PIVKA-II as a surrogate biomarker for therapeutic response in Non-AFP-secreting hepatocellular carcinoma
This study is the first to establish the "50-50 rule" for PIVKA-II response in non-AFP-secreting HCC treated with systemic therapy, highlighting its value as a surrogate marker for radiological outcomes and prognosis.
Authors
- Ming‐Huang Chen
- Yee Chao (ORCID: https://orcid.org/0000-0001-5578-340X)
- San‐Chi Chen (ORCID: https://orcid.org/0000-0002-9436-5400)
- Yi‐Ping Hung (ORCID: https://orcid.org/0000-0001-5221-6813)
- Nai‐Jung Chiang (ORCID: https://orcid.org/0000-0003-2743-9702)
- Hsiang-Ling Ho
- Chien-An Liu
- Muh-Hwa Yang
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1186/s12885-025-13568-4
- Citations
- 7
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 9.25
Funders
- Ministry of Health and Welfare
- Taiwan Clinical Oncology Research Foundation
- Taipei Veterans General Hospital